Analyst consensus rating
Genmab Analyst Rating: none
GMAB is rated none by 11 analysts with a $38.84 target. As of 2026-09-01.
Direct answer
Genmab's consensus rating is none.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $38.84.
Forecast evidence checked September 1, 2026.
Get free Genmab email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $33.48
- Average price target
- $38.84
- High price target
- $43.20
- Low price target
- $32.00
- Low target gap
- -4.4%
- Target upside
- +16%
- High target gap
- +29.1%
- Target range width
- 33.5%
- Consensus rating
- none
- Analysts
- 11
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Genmab?
Genmab has a verified none consensus. The same dataset has an average price target of $38.84.
How far are Genmab's low and high targets from the recorded price?
The low target implies -4.4%, while the high target implies +29.1%.
How many analysts are included in Genmab's consensus?
The verified consensus includes 11 analysts.
How is Genmab's target upside or downside calculated?
The average target of $38.84 is divided by the recorded price of $33.48, then one is subtracted to produce +16%. This does not guarantee a future return.
When was Genmab's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.